BioCentury
ARTICLE | Clinical News

Concert's hair loss product meets in Phase IIa, but with slower onset than Pfizer's

November 16, 2018 4:03 PM UTC

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) reported Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa products from Pfizer Inc. (NYSE:PFE).

Twice-daily 8 mg CTP-543 met the primary endpoint of a greater proportion of patients achieving a ≥50% relative reduction in overall severity of alopecia tool (SALT) score from baseline to week 24 vs. placebo (47% vs. 8.6%, p<0.001). Concert said significant differences in mean SALT scores with the 8 mg dose of CTP-543 vs. placebo were seen as early as week 12. The twice-daily 4 mg dose of CTP-543 missed the endpoint, with a 21% responder rate at week 24...